Point-of-care molecular diagnostics startup En Carta Diagnostics has raised EUR 1.5 million (USD 1.63 million) in a pre-seed funding round led by CentraleSupélec Venture, with participation from several other investors.
The raised funds will be channeled toward achieving preclinical data on a diagnostic kit prototype for chronic Lyme disease. The company also plans to use the funds to establish a robust ecosystem and enhance its market entry strategies.
Based in France, En Carta Diagnostics is a biotechnology company that develops point-of-care (POC) molecular diagnostics for various pathogens kits using synthetic biology. The company’s main therapeutic focus area is chronic Lyme disease. En Carta’s technology facilitates the creation of diagnostic kits that can be used without specialized equipment or training.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.